Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day

AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi’s 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.

Read more here:
Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day

Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET

Visit link:
Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

Delisting of AS „Grindeks” shares from the Baltic Main list

Delisting of AS „Grindeks” shares from the Baltic Main list

See the original post:
Delisting of AS „Grindeks” shares from the Baltic Main list

Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021

Bagsværd, Denmark, 12 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

View original post here:
Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021

Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed its previously announced bought deal prospectus offering of 46,000,000 units (“Units”) at a price of $0.50 per Unit for aggregate gross proceeds of $23,000,000 (the “Offering”), which includes the exercise in full of the 15% over-allotment option. The syndicate of underwriters was led by Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (together, the "Underwriters"). The Units were offered and sold by way of a short form prospectus filed with the securities commissions in each of the provinces of Canada, other than Québec.

See the article here:
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

Radius Health, Inc. Provides Abaloparatide Business Update

BOSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a business update on the abaloparatide global business. Progress was made, and continues to be made, across the following areas.

Read this article:
Radius Health, Inc. Provides Abaloparatide Business Update

New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three…

In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear biologic effects

Read the rest here:
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three...

Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line

NEW YORK, NY , Feb. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it has commenced development of its 1st full spectrum Cannabidiol (“CBD”) infused edibles product line.  The Company plans to develop this above referenced product line, with the following attributes: Kosher Certified, Halal Certified, Vegan Formulation, Dairy-Free, Infused with Full Spectrum Hemp Extract (“Full Spectrum”), All-Natural Flavors, Sugar Free/Diabetic Friendly Version(s), and Full Adherence to U.S. Federal Laws & Regulations.  The Company expects to provide concrete details about this proposed full spectrum product line within the near term.

Read the original:
Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line

Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase…

LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the closing of its previously announced underwritten public offering of 39,675,000 American Depositary Shares (“ADSs”), at a public offering price of $2.90 per ADS, which includes 5,175,000 additional ADSs issued upon the exercise in full of the underwriters’ option to purchase additional ADSs. Each ADS represents five ordinary shares of Mereo. The aggregate gross proceeds to Mereo from the offering, before deducting underwriting discounts and commissions and offering expenses were $115.1 million. All of the ADSs in the offering were sold by Mereo.

Visit link:
Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase...

Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium…

See the original post:
Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium...